Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial

IMPORTANCE: A randomized clinical trial is needed to determine whether the second-generation Abl–tyrosine kinase inhibitor dasatinib is more effective than the first-generation inhibitor imatinib mesylate for childhood Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL). OBJECTIVE: T...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JAMA Oncol
Egile Nagusiak: Shen, Shuhong, Chen, Xiaojuan, Cai, Jiaoyang, Yu, Jie, Gao, Ju, Hu, Shaoyan, Zhai, Xiaowen, Liang, Changda, Ju, Xiuli, Jiang, Hua, Jin, Runming, Wu, Xuedong, Wang, Ningling, Tian, Xin, Pan, Kaili, Jiang, Hui, Sun, Lirong, Fang, Yongjun, Li, Chi-kong, Hu, Qun, Yang, Minghua, Zhu, Yiping, Zhang, Hui, Li, Chunfu, Pei, Deqing, Jeha, Sima, Yang, Jun J, Cheng, Cheng, Tang, Jingyan, Zhu, Xiaofan, Pui, Ching-Hon
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Medical Association 2020
Gaiak:
Original Investigation
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6990720/
https://ncbi.nlm.nih.gov/pubmed/31944221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.5868
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak